Literature DB >> 31441507

Regulatory Function of Buckwheat-Resistant Starch Supplementation on Lipid Profile and Gut Microbiota in Mice Fed with a High-Fat Diet.

Yiming Zhou1, Shen Zhao2, Yue Jiang2, Yun Wei2, Xiaoli Zhou2.   

Abstract

Buckwheat-resistant starch (BRS) has shown to be a nutrient capable of lowering cholesterol and reducing obesity. In this study, the regulatory effects of tartary buckwheat starch on blood lipid level and gut microbiota (Lactobacillus, Bifidobacterium, Enterococcus, and Escherichia coli) in mice fed with a high-fat diet was investigated. Male C57BL/6 mice were separately fed with a normal diet (CON), a high-fat diet (HFD), and high-fat diet supplemented with buckwheat-resistant starch (HFD+BRS) for 6 weeks. After the feedings, lipid profile, blood glucose, plasma levels of cytokines, short-chain fatty acid content in the colon and intestinal flora of fecal were measured. Furthermore, the antioxidant indices of the liver and duodenum tissues were measured to evaluate the antioxidant capacity of mice. Significantly reduced plasma levels of total cholesterol (TC), triglyceride (TG), glucose, and cytokines were observed in the HFD+BRS group, accompanied by an increased antioxidant capacity in the liver and duodenum. In addition, supplementation with BRS significantly inhibited the increase in plasma lipopolysaccharide, tumor necrosis factor-α, and interleukin-6 levels. Gut microbiota composition was regulated by the supplement of BRS, which promoted the growth of Lactobacillus, Bifidobacterium, and Enterococcus, as well as inhibited the growth of Escherichia coli. In contrast to the HFD group, the content of short-chain fatty acids in mice colon increased in the BRS group. In conclusion, BRS benefited the cholesterol and glucose metabolism, as well as optimized gut microbiota composition in mice fed with a high-fat diet. PRACTICAL APPLICATION: This study identified the beneficial effects of tartary buckwheat-resistant starch on the regulation of blood lipids and intestinal flora in mice fed a high-fat diet. The result of this study will provide a basis for the development of probiotic products supplemented with tartary buckwheat-resistant starch and direction for further research.
© 2019 Institute of Food Technologists®.

Entities:  

Keywords:  buckwheat-resistant starch; dyslipidemia; gut microbiota; insulin resistance; profile

Mesh:

Substances:

Year:  2019        PMID: 31441507     DOI: 10.1111/1750-3841.14747

Source DB:  PubMed          Journal:  J Food Sci        ISSN: 0022-1147            Impact factor:   3.167


  5 in total

Review 1.  Amelioratory Effect of Resistant Starch on Non-alcoholic Fatty Liver Disease via the Gut-Liver Axis.

Authors:  Weifeng Zhu; Ying Zhou; Rong Tsao; Huanhuan Dong; Hua Zhang
Journal:  Front Nutr       Date:  2022-05-17

2.  Effects of Oats, Tartary Buckwheat, and Foxtail Millet Supplementation on Lipid Metabolism, Oxido-Inflammatory Responses, Gut Microbiota, and Colonic SCFA Composition in High-Fat Diet Fed Rats.

Authors:  Yong Wang; Wentao Qi; Xiaoxuan Guo; Ge Song; Shaojie Pang; Wei Fang; Zhenzhen Peng
Journal:  Nutrients       Date:  2022-07-04       Impact factor: 6.706

3.  Regulation of tartary buckwheat-resistant starch on intestinal microflora in mice fed with high-fat diet.

Authors:  Yiming Zhou; Yun Wei; Beibei Yan; Shen Zhao; Xiaoli Zhou
Journal:  Food Sci Nutr       Date:  2020-05-12       Impact factor: 2.863

4.  Octenyl Succinic Anhydride-Modified Starch Attenuates Body Weight Gain and Changes Intestinal Environment of High-Fat Diet-Fed Mice.

Authors:  Jia-Ping Chen; Kuerbanjiang Maierheba; Ying Zhang; Hui Cheng; Binbin Lin; Pan Yue; Le-Hua Wang; Feng-Zhi Liu; Jun-Wen Shi; Zhong-Xiao Wan; Xiao-Ping Wang; Jianteng Xu; Li-Qiang Qin; Yanjie Bai
Journal:  Foods       Date:  2022-09-23

5.  Gut Microbiome and Serum Metabolome Analyses Identify Unsaturated Fatty Acids and Butanoate Metabolism Induced by Gut Microbiota in Patients With Chronic Spontaneous Urticaria.

Authors:  Detong Wang; Shuping Guo; Hongxia He; Li Gong; Hongzhou Cui
Journal:  Front Cell Infect Microbiol       Date:  2020-02-21       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.